Literature DB >> 12874895

Staphylococcus aureus bacteremia and endocarditis.

Cathy A Petti1, Vance G Fowler.   

Abstract

Staphylococcus aureus is a leading cause of bacteremia and endocarditis. Over the past several years, the frequency of S aureus bacteremia (SAB) has increased dramatically. This increasing frequency, coupled with increasing rates of antibiotic resistance, has renewed interest in this serious, common infection. S aureus is a unique pathogen because of its virulent properties, its protean manifestations, and its ability to cause endocarditis on architecturally normal cardiac valves. Although the possibility of underlying endocarditis arises in virtually every patient with SAB, only a minority of bacteremic patients will actually have cardiac involvement. Distinguishing patients with S aureus infective endocarditis (IE) from those with uncomplicated SAB is essential, but often difficult. In this review, the authors summarize recent changes in the epidemiology of SAB and IE, discuss the challenges in distinguishing SAB from IE, and discuss current trends in the management of patients with SAB and IE.

Entities:  

Mesh:

Year:  2003        PMID: 12874895     DOI: 10.1016/s0733-8651(03)00030-4

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  25 in total

Review 1.  [Infective endocarditis as cardiovascular emergency].

Authors:  B Plicht; R-A Jánosi; T Buck; R Erbel
Journal:  Internist (Berl)       Date:  2010-08       Impact factor: 0.743

2.  Dentistry and Endocarditis.

Authors:  Michael J Wahl; Thomas J Pallasch
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

3.  Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia.

Authors:  Bharath Raj Palraj; Larry M Baddour; Erik P Hess; James M Steckelberg; Walter R Wilson; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2015-03-25       Impact factor: 9.079

4.  Experimental endocarditis model of methicillin resistant Staphylococcus aureus (MRSA) in rat.

Authors:  Wessam Abdel Hady; Arnold S Bayer; Yan Q Xiong
Journal:  J Vis Exp       Date:  2012-06-04       Impact factor: 1.355

5.  Live cell imaging of phagosome maturation in Staphylococcus aureus infected human endothelial cells: small colony variants are able to survive in lysosomes.

Authors:  Andreas Schröder; Raphael Kland; Andreas Peschel; Christof von Eiff; Martin Aepfelbacher
Journal:  Med Microbiol Immunol       Date:  2006-04-05       Impact factor: 3.402

6.  Issues in the Management of Endocarditis Caused by Resistant Gram-positive Organisms.

Authors:  Martin E. Stryjewski; Vivian H. Chu; Christopher H. Cabell; Vance G. Fowler
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

7.  Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia.

Authors:  Timothy Lahey; Ruta Shah; Jennifer Gittzus; Joseph Schwartzman; Kathryn Kirkland
Journal:  Medicine (Baltimore)       Date:  2009-09       Impact factor: 1.889

8.  Staphylococcus aureus Strain USA300 Perturbs Acquisition of Lysosomal Enzymes and Requires Phagosomal Acidification for Survival inside Macrophages.

Authors:  Zachary R Tranchemontagne; Ryan B Camire; Vanessa J O'Donnell; Jessfor Baugh; Kristin M Burkholder
Journal:  Infect Immun       Date:  2015-10-26       Impact factor: 3.441

Review 9.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India.

Authors:  Sheetal Chitnis; Gunjan Katara; Nanda Hemvani; Siddika Pareek; Dhananjay Sadashiv Chitnis
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.